Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...
New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...
Veeva Europe president Chris Moore talks about the company’s new genAI-powered releases and its move from Salesforce to a ...
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countriesPeople living with the rare ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...